HC Wainwright & Co. Reiterates Buy on Acelyrin, Maintains $16 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates Acelyrin (NASDAQ:SLRN) with a Buy and maintains $16 price target.

BenzingaMay 15 10:44

Buy Rating Affirmed for ACELYRIN, INC. on Solid Financials and Promising Pipeline

TipRanksMay 15 05:22

ACELYRIN, INC.: Strong Buy Recommendation on Promising Izo Drug Prospects and Strategic Advancements

TipRanksMay 14 19:25

Acelyrin | 10-Q: Quarterly report

SEC announcementMay 14 15:27 · Announcements

Calendar of U.S. Earnings Expected in the Week Ahead

Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc. Company Symbo

Dow JonesMay 13 05:00

ACELYRIN Is Maintained at Buy by HC Wainwright & Co.

ACELYRIN Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 9 13:05